KRAS Mutations - Do Survival Patterns Differ

Archived study

Examines KRAS mutation groups and post-specimen-collection survival in a public MSK pancreatic cancer cohort. Among 2,270 patients with usable outcomes, G12D and G12R median survival was 15.5 and 20.4 months. The saved age/sex/stage-adjusted G12R-versus-G12D hazard ratio was 0.769 (95% CI 0.655–0.903).

Interpretation and limits

These are exploratory observational associations, not causal mutation effects or treatment-benefit predictions. Stage violates proportional hazards, missing outcomes are imbalanced, and residual confounding remains. Survival begins at specimen collection; bounded checking did not refit the Cox models.

Package and provenance

The unchanged research package comes from the upstream archive. It retains the original conversation and included scientific artifacts, including analysis code, results and figures. The poster is an AI-generated thematic illustration, not study evidence. This introduction summarizes archived findings; the analysis was not rerun. Later bounded checks do not certify the entire study or mean the original package was corrected.

Import provenance

This case was added to the Academic Research category on 2026-10-13, with the archived upstream case recorded as its source. The supplied session export and poster were uploaded without changing their contents. This introduction summarizes the archived findings and was standardized for the repository. The study, external data sources, and scientific results were not rerun or independently reverified for this import.

This GitHub catalog imports the case from the verified Hugging Face snapshot. The session export is referenced through that fixed revision; the cover and introduction are stored in this repository.

Case files

• Session export
• Case poster